IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Detlev Sülzle

USPTO Granted Patents = 25 

 

Average Co-Inventor Count = 9.1

ph-index = 3

Forward Citations = 17(Granted Patents)


Company Filing History:

goldMedal16 out of 378 
 
Bayer Pharma Aktiengesellschaft
 patents
silverMedal7 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
bronzeMedal6 out of 443 
 
The Broad Institute, Inc.
 patents
4. 5 out of 1,206 
 
Dana-farber-cancer Institute Inc.
 patents
5. 5 out of 1,384 
 
Schering Aktiengesellschaft
 patents
6. 2 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...
Loading Chart...
25 patents (USPTO):
1. 12427153 - 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases (2025-09-30),
2. 12258323 - Dihydrooxadiazinones (2025-03-25),
3. 12227501 - 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors (2025-02-18),
4. 11773070 - Dihydrooxadiazinones (2023-10-03),
5. 11427553 - Dihydrooxadiazinones (2022-08-30),
6. 11339157 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2022-05-24),
7. 11311520 - Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors (2022-04-26),
8. 10487092 - Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors (2019-11-26),
9. 10214545 - Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders (2019-02-26),
10. 9884063 - Amido-substituted azole compounds (2018-02-06),
11. 9783543 - Aminoimidazopyridazines (2017-10-10),
12. 9777004 - Amino-substituted imidazopyridazines (2017-10-03),
13. 9745304 - Amidoimidazopyridazines as MKNK-1 kinase inhibitors (2017-08-29),
14. 9675612 - Substituted thiazolopyrimidines (2017-06-13),
15. 9643974 - Amino-substituted imidazopyridazines (2017-05-09),

Title: **Detlev Sülzle: A Pioneer in Pharmaceutical Innovations**

Introduction

Detlev Sülzle is a distinguished inventor based in Berlin, Germany. With an impressive portfolio of 22 patents, he has made significant contributions to the field of pharmaceuticals through innovative compounds and their application in treating various medical conditions.

Latest Patents

Among his latest patents, Sülzle has developed compounds such as 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one, which serve as Casein kinase 1 (CSNK1) inhibitors. This invention relates to pharmaceutical compounds that can be used in the treatment of proliferative disorders. Another notable patent involves dihydrooxadiazinones, which includes novel compounds and methods for their production. These compounds are aimed at treating hyperproliferative diseases, either as standalone agents or in combination with other active ingredients.

Career Highlights

Detlev Sülzle has held significant roles at renowned companies, particularly Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His tenure at these organizations has provided him with a platform to advance his research and focus on pharmaceuticals that have the potential to transform healthcare.

Collaborations

Throughout his career, Sülzle has collaborated with accomplished professionals such as Philip Lienau and Knut Eis. These partnerships have enriched his research endeavors and allowed for the sharing of knowledge and ideas that drive innovation in pharmaceutical development.

Conclusion

Detlev Sülzle’s contributions to the pharmaceutical industry through his patents and innovative ideas spotlight his commitment to improving health outcomes. His work exemplifies the profound impact that dedicated inventors like him can have on medical science and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…